Odyssey Therapeutics presents Phase 2a trial design for OD-001 plus vedolizumab in ulcerative colitis at ACG 2026

• Odyssey Therapeutics will present the design of a Phase 2a trial of OD-001 with vedolizumab in ulcerative colitis at ACG 2026.
• The study tests a combination approach intended to curb intestinal inflammation, then switches patients to OD-001 alone for longer-term maintenance.
• Enrollment is expected to reach up to 146 patients globally, with a 12-week induction period followed by treatment through Week 52.
• Prior Phase 2a proof-of-concept results for OD-001 monotherapy were previously reported, with no new efficacy results disclosed in this release.
• Topline induction results from the combination trial are expected in the second half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Odyssey Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610120800PRIMZONEFULLFEED9843561) on October 12, 2026, and is solely responsible for the information contained therein.